Fewer than a tenth of patients who could benefit from obesity jabs such as Wegovy are able to get them, warns the global health agency as it issues its inaugural guidance on the therapies.
With in excess of 1,000,000,000 people worldwide currently classified as obese, it is advocating for increased and just availability to these injectable treatments.
According to estimates, over two billion could be obese by 2030 without intervention.
"Our new guidance affirms that obesity is a lifelong illness that can be treated with thorough and lifelong treatment," said the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are significant obstacles to widespread access to the injections that can help people shift considerable weight, explains the body.
Weight-Loss Drug Supply Crisis
Despite the current most optimistic case, the supply of GLP-1 therapies could only cover around 100 million people – fewer than 10% of eligible patients, as stated by the health organization.
The recommendation urges governments and firms to increase access, via approaches like licensing agreements.
Exclusive production rights on semaglutide – the main component of the drug Wegovy – is scheduled to end in several nations in 2026.
How Weight-Loss Jabs Work
GLP-1 drugs replicate a biological compound to delay gastric emptying, curb appetite and increase feelings of fullness so individuals reduce food intake.
Patients commonly see weight reduction within a few weeks of beginning the once-weekly jabs.
Research points to users may see weight return within a year of stopping the drug, because their normal appetite return.
Being carrying excess weight increases your chance for contracting medical conditions, including diabetes, heart disease, brain attack, and certain malignancies.
Excess weight affects people in every country and was responsible for millions of fatalities worldwide in 2024, as per the WHO.
